The global vascular access devices market size was estimated at USD 8.64 billion in 2024 and is projected to reach USD 11.49 billion by 2030, growing at a CAGR of 4.7% from 2025 to 2030. Market growth over the forecast period is expected to be significantly influenced by changing patient demographics worldwide. The expanding geriatric population, along with the rising prevalence of cancer and other chronic conditions such as cardiovascular, respiratory, and metabolic disorders, is increasing the number of patients requiring vascular access devices for diagnosis, treatment, and long-term therapy management. These conditions often necessitate frequent or prolonged intravenous access for drug administration, chemotherapy, dialysis, and nutritional support, thereby supporting steady market expansion in line with the growing patient pool.

Furthermore, increasing awareness regarding the financial burden associated with catheter-related complications within healthcare institutions is supporting the adoption of safer and more reliable vascular access solutions. Complications such as infections, thrombosis, and device failure can lead to extended hospital stays and higher treatment costs, prompting healthcare providers to prioritize products that help reduce complication rates. Clinical investigations have demonstrated that improper usage, insertion techniques, and maintenance of vascular access devices can result in significant adverse outcomes. As a result, manufacturers are increasingly differentiating their products by offering comprehensive training and education programs, either online or in person, to improve clinical outcomes and strengthen end-user confidence.

These training initiatives also help manufacturers foster long-term brand loyalty among healthcare professionals by ensuring correct device usage and adherence to best practices. Programs such as the Teleflex Academy from Teleflex Medical and the Clinical Training programs offered by BD serve as notable examples of successful educational initiatives that support product adoption and enhance patient safety outcomes.

Key Market Trends & Insights:

• The North America vascular access devices market held a substantial revenue share of 53.35% in 2024. Market growth in the region is primarily driven by the shift toward value-based care models in the U.S., which emphasize improved patient outcomes and cost efficiency and support the adoption of established vascular access devices with proven clinical benefits. Additionally, the increasing incidence of cancer and rising demand for chemotherapy treatments continue to drive growth in the U.S. vascular access devices market, as these therapies require reliable and long-term vascular access.
• Based on product type, the short peripheral intravenous catheter (Short PIVC) segment dominated the market, accounting for more than 44.0% of total revenue in 2024. The segment is expected to continue growing over the forecast period, largely due to the high frequency of Short PIVC use in clinical settings. These devices represent the most commonly performed invasive procedure by healthcare professionals and are widely used for short-term intravenous therapy in hospitals and outpatient facilities.
• Based on end use, the hospital-based segment dominated the market with a revenue share of more than 50.2% in 2024. Hospitals remain the primary setting for vascular access device utilization due to the high volume of inpatient procedures, critical care treatments, and complex therapies. Meanwhile, the ambulatory care and surgical centers (ASCs) segment is experiencing substantial growth, driven by the increasing preference for outpatient procedures among both patients and healthcare providers, along with advancements in minimally invasive treatments.

Order a free sample PDF of the Vascular Access Devices Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 8.64 billion
• 2030 Projected Market Size: USD 11.49 billion
• CAGR (2025-2030): 4.7%
• North America: Largest market in 2024

Key Companies & Market Share Insights:

Key players operating in the vascular access devices market are focusing on strategies such as launching innovative products, pursuing strategic acquisitions, and investing in technological advancements to expand and complement their existing product portfolios. Competition among market participants is intensifying due to the growing demand for technologically advanced vascular access devices that offer improved safety, ease of use, and reduced complication risks.

Some of the prominent companies in the market include BD, B. Braun, Teleflex, Terumo, Medcomp/Medical Components, Inc., and Vygon SA. BD is a leading player in the market, supported by its acquisition of C. R. Bard, which added an extensive portfolio of market-leading products spanning nearly all segments of the vascular access devices market. The rising number of product approvals, new market entrants, and effective distribution agreements has further increased competitive intensity. As a result, industry competition is expected to remain strong throughout the forecast period, encouraging continuous innovation and product differentiation.

Key Players

• Teleflex Medical
• BD
• Braun
• Smith’s Medical (ICU Medical, Inc)
• Cook Medical
• AngioDynamics
• Medtronic
• Medical Components, Inc.
• Cook Medical
• Terumo Medical Corporation
• Access Vascular, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the vascular access devices market is expected to grow steadily, driven by the expanding geriatric population and the rising prevalence of chronic diseases such as cancer and cardiovascular disorders. Increasing awareness of the costs and clinical risks associated with catheter-related complications is encouraging healthcare providers to adopt safer and more reliable vascular access solutions. Hospitals continue to dominate usage, while ambulatory care and surgical centers are emerging as fast-growing end-use settings due to the shift toward outpatient care. North America remains the leading regional market, supported by value-based care initiatives and high chemotherapy demand. Ongoing product innovation, strategic acquisitions, and clinician training programs are strengthening market competitiveness. Collectively, these factors are anticipated to support sustained market growth through 2030.